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Abstract  
Proliferation of different brands of antibiotics including ampiclox (a notable penicillinase 
inactivator) was considered a relevant factor in the antibiotic resistance of Staphylococcus  
aureus. Consequently the antibiogram and susceptibility of 20 clinical strains and a control 
strain (NCTC 6571) of Staphylococcus aureus to 10 different brands of ampiclox were 
determined by disk diffusion and tube broth dilution methods. The control strain was 
found sensitive to ampicilin, augmentinR and cloxacillin in the antibiogram, and to all the l0 
brands of ampiclox, with the MIC's of either 0.125 or 0.25µg/mI among the clinical strains. 
This result, compared with the MIC's obtained in the range of 0.125µg/ml to > 60µg/mI, 
varying among the brands of ampiclox against the 20 clinical strains, indicates contrasting 
inhibitory activity among the different brands but reflective of the worrisome level of 
resistance to antibiotics by Staph. aureus. However, this resistance to most of the brands of 
ampic1ox could not be associated with brand variation having found the control strain 
sensitive to all the brands of ampiclox.  
INTRODUCTION  
Ampiclox is a Beta-lactam combination 
antibiotic comprising ampicillin (an -
aminobenzylpenicillin) and cloxacillin, 
both of which are still obtainable as 
individual penicillins. Ampicillin and 
cloxacillin represent an improvement  
over the parent penicillins (penicillin 
G, penicillin V and benzathine 
penicillin) in terms of stability in the 
presence of the gastric juice acid and 
(Beta-1actam drug inactivating 
enzymes - penicillinase and 
cephalosporinase and spectrum of  
 
 
antimicrobial activity(l). Though  
ampillin is susceptible to the action of 
(Beta-1actamase{2), a deficiency that 
accounts for its combination with 
cloxacillin, thus producing a synergy  
in the antibacterial activity of 
ampiclox. However, there have been 
reports of multiple drug resistant 
staphylococci to antimicrobial 
agents(3,4,5). In this episode of 
multiple drug resistance (MDR) 
ampicillin, amoxicillin and cloxacillin 
(6) as well as other Beta-lactamase 





not been excluded: amoxicillin-
clavulanate, methicillin, vancomycin, 
and cephalosporins (7,8,9,1O,1I,12, 13). 
The MDR in Staphylococcus aureus has' 
been largely attributed to resistance 
genes borne on R-plasmid DNA(l4). 
Notably, the hospital strains of this 
organism have been greatly 
implicated(l5). Staph aureus is an 
important cause of community and 
hospital acquired infections (l6,17). 
Besides plasmid, high-level resistance 
could also occur from a low level 
through a multistep process due to 
chromosomal gene .alteration(18). 
Among the enormous number of 
antibiotics avmlable, pencillin 
antibiotics are recognizably the most 
commonly used. This could explain the 
high level of production of these 
antibiotics in different forms-single, 
combination and different brands. 
Antibiotic prescribing has been 
observed to be in favour of some 
particular brands of antibiotics 
particularly, ampiclox(19). Hence, the 
need for this study to evaluate the 
antimicrobial potency of available 
different brands of ampiclox.  
 
MATERIALS AND METHODS  
BACTERIOLOGY  
Strains of Staphylococcus aureus from 
different clinical sources, numbering 
20, were collected from the Medical 
Microbiology Laboratory, University 
College Hospital (U.C.H.), Ibadan and 
General Bacteriology Laboratory, 
Lagos University Teaching Hospital 
(LUTH), Lagos, Nigeria (Table 1). All 
the clinical strains were screened for 
purity by means of some coagulase test 
with reference to a control preserved 
on Nutrient agar (OXOID) slants at 4°C 
in a refrigerator until when they were 
needed.  
ANTIBIOTICS  
Ten brands of ampiclox (powder for 
injection) were purchased from local 
pharmacy shops, and given codes as : 
EL, PH, JA, CL, ML, RS, SK, RH, TR.  
Antibiotic Disks (Abtek Biological 
Ltd.): AugmentinR {30µg), Amoxicillin 
(25µg), Erythromycin (5µg), 
Tetracycline (10µg), Cotrimoxazole 
(25µg), Chloramphenicol (30µg), 
Cloxacillin (5µg), Gentamicin (10µg).  
 
ANTIBIOGRAM  
The antibiotic susceptibility pattern of 
each strain of Staph. aureus was 
determined by the Kirby-Bauer's Disk-
Diffusion method as previously 
described(21). The inoculum size of 
each strain was 107 cells/ml in O.lml 
taken from 10-2 dilution of overnight 
broth culture, as determined in a pour-
plate culture. All the culture and 
sensitivity plates were incubated at 
37°C for 24hrs. Zones of growth 
inhibition were then observed and 





determine sensitivity or resistance to a 
particular antibiotic disc (Table 2).  
MINIMUM INHIBITORY 
CONCENTRATIONS (MIC) OF THE 
BRANDS OF AMPICLOX  
The tube-broth dilution method was 
used to determine MIC. Suitable high 
aq. stock concentrations of each brand 
of ampiclox were prepared to provide 
60, 50, 20, and 4µg/rnl, in four 
different tubes of 10ml nutrient broth 
(OXOD) each. Serial dilutions were 
made also in nutrient broth to give the 
following antibiotic concentrations: 30, 
25, 10, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625 
and 0.031µg/m1. Each dilution was 
then inoculated with O.lml from 10-2 
aq. dilution (equivalent to 107 
cells/ml) of an overnight broth 
culture. The mixtures were then 
incubated at 37°C for 24hrs, followed 
by observation for sensitivity or 
resistance revealed by the visibility of 
turbidity in each tube to determine the 
MIC.  
RESULTS  
In the antibiogram for the clinical 
strains of Staph aureus, amoxicillin, 
augmentinR (amoxicillin-clavulanate) 
and cloxacillin showed no zone of 
growth inhibition, but did so for the 
control strain, NCfC 6571. Gentamicin 
and chloraphenicol were relatively 
outstanding in their anti-
staphylococcal activity (Table 2). 
Among the 10 brands of ampiclox, 9 
brands exhibited reasonable activity of 
MIC 0.125 - 0.5µg/ml (Table 3) against 
9 of the clinical strains (i.e. 45%) of 
Staph. aureus at different levels: BH (5 
strains), SK (2 strains), TR (1 strain) 
RH (1 strain) and CL (4 strains). Thus, 
one coded EL lacked activity against 
any one of the clinical strains. These 
variations are reflected as percentage 
resistant pattern of the clinical strains 
(Table 4). However, everyone of the 
ampiclox brands produced MIC of 
either 0.125µg/ml or 0.25µg/ml against 
the control strain of Staph. aureus, 





TABLE 1: THE CLINICAL STRAINS OF STAPHYLOCOCCUS AUREUS  
Strain of  Clinical source/                 Strain of                          Clinical source/   
S. aureus  Control 
0263   Endorcervical swab 
0273   Wound swab 
0301   Ear Swab 
1122   Sputum 
1503   Nasal swab 
1559   Eye swab 
2464   Sputum 
2994   Sputum 
3409   Wound swab 
3413   High Vaginal swab  
078   Wound swab 
 
 
S. aureus                                Control 
086   HVS 
0342   Eye swab 
0748   HVS 
1937   Urethral swab 
1950   Wound swab 
1970   Ear swab 
1975   Sinus effluent 
5626   Blood 
17322   Ear swab 
NCTC 6571  Type culture 
 






Cloxacillin is used to treat B-Iactamase 
(penicillinase) - producing 
staphylococci(6) due to the presence of 
isoxazolyl as an added group(1) in the 
antibiotic. The resistance to this 
antibiotic (cloxacillin) by all the 20 
clinical strains in the antibiogram and 




brands indicates a strong possibility of 
the clinical strains as Blactamase 
bearers. The sensitivity noted for the 
control Oxford strain of Staph. au reus 
NCfC 6571 to cloxacillin both in the 
antibiogram and the ampiclox brands 
(at MIC of either 0.12511g/ml or  






TABLE 2:  ANTIBIOGRAM OF THE CONTROL NCTC 6571 AND CLINICAL STRAINS OF 
STAPHYLOCOCCUS AUREUS 
 
      Antibiotic disk(µ.g)   
Strain of  Aug  Amx  Ery  Tet  Cxc  Gen  Cot  ChI  
S.aureus           
NCTC  20.0*  18.0  22.2  25.5  21.5  23.1  6.4  14.0  
6571           
078  ** -  -  -  -  -  -  -  -  
086  -  -  -  -  -  17  -  -  
0342  -  -  -  -  -  -  -  -  
0748  -  -  -  -  -  -  -  -  
1937  -  -  -  -  -  16  -  -  
      'i     
1950  -  -  -  -  -  17  -  15  
1970  -  -  -  -  -  15  -  -  
1975  -  -  -  -  -  23  22  25  
5626  -  -  -  -  -  -  -  -  
17322  -  -  -  -  -  -  -  10  
0263  -  -  -  -  -  16  -  -  
0273  -  -  -  -  -  15  -  -  
0301  -  -  -  -  -  13  -  -  
1122  -  -  -  -  -  -  -  -  
1503  -  -  -  -  -  12  10  10  
1559  -  -  -  -  -  17  12  11  
2464  -  -  -  -  -  24  22  18  
2994  -  -  -  -  -  12  10  9.0  
3409  -  -  -  -  -  13  11  10  
3413  -  -  -  -  -  21  15  13  
KEY: Aug: augmentin (30µg)                        Amx = amoxicillin (25µg) .  
 Ery: Erythromycin (5µg)                                Tet = Tetracycline (10µg)  
 Cxc: Cloxacillin (10µg)                                    Gen = Gentamicin (10µg)  
Cot: = Cotrimoxazole (10µg)                           ChI = Chloramphenicol (20µg)  















SK ML RH RS EL PH JA TR CL 
0263  > 60  > 60  >60  > 60  1.0  > 60  1.0  30  50  20  
5626  > 60  > 60  >60  > 60  1.0  > 60  1.0  30  50  30  
0273  0.25  > 60  >60  > 60  2.0  2.0  2.0  > 60  > 60  . > 60  
078  0.25  20  >60  > 60  2.0  50  0.25  0.5  5.0  0.25  
0301  > 60  > 60  > 60  > 60  5.0  > 60  > 60  > 60  > 60  > 60  
086  > 60  > 60  > 60  > 60  1.0  > 60  > 60  > 60  > 60  > 60  
1122  > 60  > 60  > 60  > 60  > 60  > 60  > 60  > 60  > 60  > 60  
0748  > 60  > 60  > 60  > 60  > 60  > 60  > 60  > 60  > 60  > 60  
1503  2.0  > 60  > 60  > 60  2.0  > 60  > 60  1.0  2.0  10  
1559  0.25  > 60  > 60  > 60  0.5  > 60  0.125  0.5  2.0  0.25  
0342  0.125  0.5  20  5.0  0.25  20  0.125  1.0  5.0  0.5  
2464  0.0  5.0  1.0  2.0  0.125  30  10  5.0  0.25  0.5  
1937  10  0.125  0.25  1.0  0.5  20  0.25  0.125  1.0  0.125  
1950  20  10.0  0.125  0.5  0.5  > 60  0.125  0.25  5.0  5.0  
2994  > 60  > 60  > 60  > 60  > 60  > 60  > 60  > 60  > 60  > 60  
1970  > 60  > 60  > 60  > 60  > 60  > 60  > 60  > 60  > 60  > 60  
3409  10  > 60  > 60  > 60  4.0  > 60  > 60  10  > 60  10  
1975  > 60  > 60  > 60  > 60  > 60  > 60  > 60  > 60  > 60  > 60  
3413  2.0  > 60  > 60  > 60  0.5  > 60  > 60  10  > 60  5.0  
3413  2.0  > 60  > 60  > 60  0.5  > 60  > 60  10  > 60  5.0  
17322  025  10  > 60  > 60  > 60  > 60  0.5  > 60  > 60  > 60  
NCTC 
 
0.125  0.125  0.125  0.125  0.25  0.5  0.25  0.25  0.5  0.125  







TABLE 4: RESISTANCE PATTERN OF THE CLINICAL STRAINS OF STAPH. AURUES AGAINST 
10 BRANDS OF AMPICLOX . 
 
 Brands of Ampiclox    No of resistant isolates                                    percentage (%)  
BH    15     75 
SK    18     90 
ML    18     90 
RH    19     95 
RS    14     70 
EL    20     100 
PH    14     70 
JA    16     80 
TR    19     95 
CL    15     75 
The variation noted in the activity of 9 
out of 10 brands of ampiclox against 9 
out 20 clinical strains of Staph aureus 
and the inactivity of one brand of 
ampiclox (EL) against none of the 20 
clinical strains, corroborates the report 
of higher demand of one particular 
brand of ampiclox than the demand 
for other (19). There is need therefore, 
for continuous monitoring of the 
brands of antiobiotics with respect to  
their activity on relevant bacteria from 
clinical sources. Having found the  
control strain, Staph.aureus NCfC 6571, 
sensitive to the 10 brands of ampiclox 
tested, the resistance noted in this 
study among the 20 clinical strains to 
most of the brands of ampiclox could 
not be associated with variation in the 
brands.  
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